Biomind is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind’s current development focus is on fast-acting psychedelic molecules given the challenges in creating adequate clinical protocols to provide patients with access to affordable and modern day psychedelic treatments.